Neuronata-R retains conditional approval in South Korea
Neuronata-R retains conditional approval in South Korea PR Newswire SEOUL, South Korea, July 19, 2026
EMA - Emera Incorporated
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$52.00
DETAILS
HIGH:
$52.00
LOW:
$52.00
MEDIAN:
$52.00
CONSENSUS:
$52.00
DOWNSIDE:
5.13%
Stock News
CORRECTING and REPLACING Emera Declares Quarterly Dividends
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Series J First Preferred Share quarterly dividend in release dated July 13, 2026, should read: $0.39660 (instead of $0.265625). The updated release reads EMERA DECLARES QUARTERLY DIVIDENDS On July 13, 2026, the Board of Directors of Emera Inc. (TSX/NYSE: EMA) declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 17, 2026 to the applicable shareholders of record at the close of business on.
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy ag
Emera Declares Quarterly Dividends
HALIFAX, Nova Scotia--(BUSINESS WIRE)--On July 13, 2026, the Board of Directors of Emera Inc. (TSX/NYSE: EMA) declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 17, 2026 to the applicable shareholders of record at the close of business on August 3, 2026, as follows: $0.7325 per common share; $0.3094 per Series A First Preferred Share; $0.40213 per Series C First Preferred Share; $0.28125 per Series E First Preferred Share;.
Emera Teleconference on August 7 to Discuss Q2 2026 Results
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today Emera (TSX/NYSE: EMA) announced that it will release its Q2 2026 results on Friday, August 7, 2026, before markets open. The Company will host a teleconference and webcast the same day at 9:30 a.m. Atlantic (8:30 a.m. Eastern) to discuss the results. Analysts and other interested parties in North America are invited to participate by dialing 1-800-717-1738. International parties are invited to participate by dialing 1-289-514-5100. Participants shoul.
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dise
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) acro
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility PR Newswire SINGAPORE,
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Johnson and Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Johnson and Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocyti
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
Emera Inc. Announces Election of Directors
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) announced that at its Annual Meeting of Shareholders held on May 21, 2026, on a vote by ballot, each of the 11 nominees proposed as Directors and listed in its Management Information Circular dated as of March 19, 2026 were elected as Directors. The detailed results of the vote for the election of Directors are set out below. Nominee Votes For Votes Withheld Number Percent Number Percent Scott C. Balfour 158,298,930 99.75% 390,.
Emera Incorporated (EMA:CA) Shareholder/Analyst Call Transcript
Emera Incorporated (EMA:CA) Shareholder/Analyst Call Transcript